Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF versus G-CSF alone
暂无分享,去创建一个
G. Tricot | J. Kanda | J. Liesveld | A. Sung | N. Chao | M. Horwitz | L. Holmberg | P. Shaughnessy | B. Mcclune | Stephen T Brown | D. Grima | G. Carrum | L. Bernard
[1] L. Rybicki,et al. Etoposide plus G-CSF priming compared with G-CSF alone in patients with lymphoma improves mobilization without an increased risk of secondary myelodysplasia and leukemia , 2012, Bone Marrow Transplantation.
[2] V. Roy,et al. Efficacy and cost‐benefit analysis of risk‐adaptive use of plerixafor for autologous hematopoietic progenitor cell mobilization , 2012, Transfusion.
[3] A. Pickard,et al. Outcome, toxicity profile and cost analysis of autologous stem cell mobilization , 2011, Bone Marrow Transplantation.
[4] U. Popat,et al. Assessing the charges associated with hematopoietic stem cell mobilization and remobilization in patients with lymphoma and multiple myeloma undergoing autologous hematopoietic peripheral blood stem cell transplantation , 2011, Transfusion.
[5] Julie A. Murphy,et al. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[6] R. Stuart,et al. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization , 2011, Bone Marrow Transplantation.
[7] J. Vose,et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[8] H. Goldschmidt,et al. Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[9] L. Gordon,et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[10] M. Gertz,et al. Clinical Impact and Resource Utilization After Stem Cell Mobilization Failure in Patients with Multiple Myeloma and Lymphoma. , 2009 .
[11] A. Nademanee,et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] A. Nademanee,et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. , 2009, Blood.
[13] U. Popat,et al. Poor hematopoietic stem cell mobilizers: A single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma , 2009, American journal of hematology.
[14] Michael L. Wang,et al. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[15] J. Dipersio,et al. Improving stem cell mobilization strategies: future directions , 2009, Bone Marrow Transplantation.
[16] P. Ravaud,et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] J. Dipersio,et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. , 2005, Blood.
[18] Thomas Fleming,et al. Red book : pharmacy's fundamental reference , 2004 .
[19] G. Morgan,et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. , 2003, The New England journal of medicine.
[20] I. Petit,et al. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. , 2002, Experimental hematology.
[21] M. Bhatia,et al. Number of viable CD34+ cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation , 2002, Bone Marrow Transplantation.
[22] E. Ashihara,et al. Infusion of a high number of CD34+ cells provides a rapid hematopoietic recovery and cost savings in autologous peripheral blood stem cell transplantation. , 2002, Japanese journal of clinical oncology.
[23] D. Schenkein,et al. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. , 2001, Blood.
[24] E. Gaarsdal,et al. A comparative study of sequential priming and mobilisation of progenitor cells with rhG-CSF alone and high-dose cyclophosphamide plus rhG-CSF , 2000, Bone Marrow Transplantation.
[25] E. Scarpi,et al. Is There Any Difference in PBPC Mobilization Between Cyclophosphamide Plus G-CSF and G-CSF Alone in Patients with Non-Hodgkin's Lymphoma? , 2000, Leukemia & lymphoma.
[26] T. Lister,et al. Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma. , 2000, The hematology journal : the official journal of the European Haematology Association.
[27] V. Diehl,et al. Using at least 5×106/kg CD34+ cells for autologous stem cell transplantation significantly reduces febrile complications and use of antibiotics after transplantation , 1999, Bone Marrow Transplantation.
[28] N. Schmitz,et al. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] R. Bouabdallah,et al. Autologous transplantation of blood stem cells mobilized with filgrastim alone in 93 patients with malignancies: the number of CD34+ cells reinfused is the only factor predicting both granulocyte and platelet recovery. , 1996, Journal of hematotherapy.